KYRIX
Live / Applied — First extension granted (statement of use) (as of 17 Dec 2025)
What this means for you
Not registered yet, but its 15 May 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97411368
- Mark type
- Stylized text
- Filed
- 15 May 2022
- Published for opposition
- 31 Dec 2024
- Attorney of record
- Timur Slonim
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biopharmaceutical preparations, excluding vaccines for human use, for the treatment and prevention of cancer, fibrosis, and inflammatory diseases for therapeutical applications excluding prescription pharmaceutical and medicinal preparations for the treatment and prevention of kidney diseases and disorders, administered in any way other than topically, and excluding anti-inflammatories
- Class 042 — Scientific and technological services: Pharmaceutical and biopharmaceutical drug development services; pharmaceutical and biopharmaceutical drug discovery services; pharmaceutical and biopharmaceutical research services
Owner
- Bridge Biotherapeutics Inc., Newton,, MA, US
- Bridge Biotherapeutics Inc., Newton,, MA, US
Prosecution history
- 17 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Dec 2025 — SOU EXTENSION 1 GRANTED
- 17 Dec 2025 — SOU EXTENSION 1 FILED
- 17 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 17 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 11 May 2025 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 11 Apr 2025 — POST PUBLICATION AMENDMENT - ENTERED
- 11 Apr 2025 — ASSIGNED TO PETITION STAFF
- 07 Mar 2025 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 23 Jan 2025 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 31 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 31 Dec 2024 — PUBLISHED FOR OPPOSITION
- 25 Dec 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 05 Dec 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 04 Dec 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED